Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

316 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment.
Schnell D, Buschke S, Fuchs H, Gansser D, Goeldner RG, Uttenreuther-Fischer M, Stopfer P, Wind S, Petersen-Sylla M, Halabi A, Koenen R. Schnell D, et al. Cancer Chemother Pharmacol. 2014 Aug;74(2):267-75. doi: 10.1007/s00280-014-2484-y. Epub 2014 Jun 7. Cancer Chemother Pharmacol. 2014. PMID: 24906422 Free PMC article. Clinical Trial.
Clinical Pharmacokinetics and Pharmacodynamics of Afatinib.
Wind S, Schnell D, Ebner T, Freiwald M, Stopfer P. Wind S, et al. Among authors: schnell d. Clin Pharmacokinet. 2017 Mar;56(3):235-250. doi: 10.1007/s40262-016-0440-1. Clin Pharmacokinet. 2017. PMID: 27470518 Free PMC article. Review.
A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours.
Suder A, Ang JE, Kyle F, Harris D, Rudman S, Kristeleit R, Solca F, Uttenreuther-Fischer M, Pemberton K, Pelling K, Schnell D, de Bono J, Spicer J. Suder A, et al. Among authors: schnell d. Eur J Cancer. 2015 Nov;51(16):2275-84. doi: 10.1016/j.ejca.2015.07.041. Epub 2015 Aug 18. Eur J Cancer. 2015. PMID: 26296295 Clinical Trial.
Pharmacokinetics of Nintedanib in Subjects With Hepatic Impairment.
Marzin K, Kretschmar G, Luedtke D, Kraemer S, Kuelzer R, Schlenker-Herceg R, Schmid U, Schnell D, Dallinger C. Marzin K, et al. Among authors: schnell d. J Clin Pharmacol. 2018 Mar;58(3):357-363. doi: 10.1002/jcph.1025. Epub 2017 Nov 6. J Clin Pharmacol. 2018. PMID: 29106740 Free PMC article. Clinical Trial.
A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma.
Palmer DH, Ma YT, Peck-Radosavljevic M, Ross P, Graham J, Fartoux L, Deptala A, Studeny M, Schnell D, Hocke J, Loembé AB, Meyer T. Palmer DH, et al. Among authors: schnell d. Br J Cancer. 2018 May;118(9):1162-1168. doi: 10.1038/s41416-018-0051-8. Epub 2018 Mar 22. Br J Cancer. 2018. PMID: 29563636 Free PMC article. Clinical Trial.
316 results